Form 4: Zoetis CFO Wetteny Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Zoetis Inc. CFO Joseph Wetteny reports the acquisition of stock options and restricted stock units (RSUs) in a recent Form 4 filing.
Summary
- Joseph Wetteny, CFO of Zoetis Inc., filed a Form 4 detailing changes in beneficial ownership.
- The filing reports the acquisition of 6,064 restricted stock units (RSUs) on February 19, 2025, which vest in three equal installments annually from the grant date.
- Wetteny also acquired 23,625 stock options with an exercise price of $156.64, vesting similarly over three years from February 19, 2025.
- The filing also details existing holdings of RSUs and stock options granted in previous years (2022, 2023 and 2024) with varying vesting schedules and exercise prices.
- All stock options expire ten years from the grant date.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of management with shareholder interests. It's a neutral to slightly positive signal.
Positives
- The grant of RSUs and stock options aligns the CFO's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CFO.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Equity grants are a common practice in the pharmaceutical industry to incentivize and retain key executives. The vesting schedules are designed to align management's interests with long-term shareholder value.
Comparison to Industry Standards
- Stock option and RSU grants are standard compensation practices among publicly traded companies, including Zoetis's competitors like Elanco Animal Health and Merck Animal Health.
- The vesting schedules (typically three years) are also in line with industry norms to ensure executive retention and alignment with long-term performance.
- The specific number of options and RSUs granted would need to be compared against peer companies to determine if the compensation package is above, below, or in line with industry averages for CFOs.
Stakeholder Impact
- Shareholders: The equity grants align management's interests with shareholder value.
- Employees: The grants can serve as a positive signal regarding the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 02/08/2022 | Date of grant for existing stock options with an exercise price of $201.3, vesting on the third anniversary. |
| 02/08/2023 | Date of grant for existing RSUs and stock options, vesting in three equal installments annually from the grant date. |
| 02/06/2024 | Date of grant for existing RSUs and stock options, vesting in three equal installments annually from the grant date. |
| 02/19/2025 | Date of transaction: Grant of 6,064 RSUs and 23,625 stock options with an exercise price of $156.64. |
| 02/21/2025 | Date of Form 4 filing. |
Keywords
Form 4, Zoetis, Stock Options, Restricted Stock Units, RSU, ZTS, Beneficial Ownership, Wetteny, CFO, Equity Incentive Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.